SCHEMBL1893064

SCHEMBL1893064

CN1CCC(Oc2ccc(C(=O)Nc3n[nH]c4c3CN(S(=O)(=O)c3cc(F)cc(F)c3)CC4)c(NC(=O)[C@H]3CCCO3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 9/20 0.55
INSR P06213 7/20 0.47
ALK Q9UM73 7/20 0.47
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 4/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
AURKA O14965 2/20 0.36
AURKB Q96GD4 2/20 0.36
HSD17B10 Q99714 1/20 0.36
PLK4 O00444 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884810 1.00 IGF1R (0.55) IGF1RINSRALKSMN1; SMN2LMNA
SCHEMBL1886569 0.95 IGF1R (0.53) IGF1RINSRALKSMN1; SMN2LMNA
SCHEMBL1893738 0.95 IGF1R (0.53) IGF1RINSRALKSMN1; SMN2LMNA
SCHEMBL1890616 0.91 IGF1R (0.53) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1888115 0.91 IGF1R (0.53) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1885270 0.90 IGF1R (0.56) IGF1RINSRALKCCNA2CDK2
SCHEMBL1885554 0.89 IGF1R (0.54) IGF1RINSRALKCCNA2CDK2
SCHEMBL1887859 0.89 IGF1R (0.46) IGF1RINSRALKSMN1; SMN2LMNA
SCHEMBL1885576 0.89 IGF1R (0.46) IGF1RINSRALKSMN1; SMN2LMNA
SCHEMBL1885716 0.88 IGF1R (0.62) IGF1RINSRALKCCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885INSR 922/4885ALK 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.